Voices From TCT 2015: Ken Stein On The Future Of Watchman
This article was originally published in The Gray Sheet
Executive Summary
In an exclusive podcast interview with "The Gray Sheet," Ken Stein, Boston Scientific's chief medical officer for cardiac rhythm management, says the company is well positioned to expand adoption of its novel Watchman left-atrial appendage closure device after a challenging regulatory process. He says CMS' recent denial of a new-technology add-on payment is actually good news for the device and the company is looking forward to that agency establishing a national coverage policy.
You may also be interested in...
Boston Sci's Watchman Gets Positive Medicare Coverage Policy
CMS granted national coverage for left atrial appendage closure procedures to prevent stroke under more favorable conditions than what the Medicare agency had proposed in November. This is good news for Boston Scientific, which is ramping up marketing of its Watchman device.
Boston Sci's Watchman Gets Positive Medicare Coverage Policy
CMS granted national coverage for left atrial appendage closure procedures to prevent stroke under more favorable conditions than what the Medicare agency had proposed in November. This is good news for Boston Scientific, which is ramping up marketing of its Watchman device.
CMS Proposes CED Policy For Watchman With Some Unexpected Conditions
The proposed national coverage decision for the left-atrial appendage closure stroke device would grant Medicare coverage with stipulations, including one provision that appears to contradict a key element of FDA labeling and a challenging registry requirement.